Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Shares Outstanding (Diluted Average) (2017 - 2025)

Historic Shares Outstanding (Diluted Average) for Silo Pharma (SILO) over the last 9 years, with Q3 2025 value amounting to $9.3 million.

  • Silo Pharma's Shares Outstanding (Diluted Average) rose 11691.49% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 11691.49%. This contributed to the annual value of $3.7 million for FY2024, which is 1949.8% up from last year.
  • Per Silo Pharma's latest filing, its Shares Outstanding (Diluted Average) stood at $9.3 million for Q3 2025, which was up 11691.49% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Silo Pharma's Shares Outstanding (Diluted Average) registered a high of $96.9 million during Q2 2021, and its lowest value of $1.9 million during Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $3.1 million (2023), whereas its average is $12.7 million.
  • In the last 5 years, Silo Pharma's Shares Outstanding (Diluted Average) crashed by 9794.76% in 2022 and then soared by 11691.49% in 2025.
  • Quarter analysis of 5 years shows Silo Pharma's Shares Outstanding (Diluted Average) stood at $1.9 million in 2021, then rose by 19.07% to $2.3 million in 2022, then skyrocketed by 34.83% to $3.1 million in 2023, then grew by 19.5% to $3.7 million in 2024, then surged by 153.54% to $9.3 million in 2025.
  • Its last three reported values are $9.3 million in Q3 2025, $6.3 million for Q2 2025, and $4.5 million during Q1 2025.